If your gastroenterologist has prescribed Tremfya for Crohn's disease and you carry a Blue Cross Blue Shield card, the honest answer to whether it is covered is that it depends on which Blue plan you have. Tremfya, the brand name for guselkumab, only received FDA approval for moderately to severely active Crohn's disease in 2025, so it is one of the newest options in the Crohn's toolbox. Because Blue Cross Blue Shield is not a single insurer but a federation of independent companies, coverage rules, formulary tier, and the hoops you have to clear differ from one state and plan to the next. This article explains why that variation exists and how to find the answer for your own policy.
Why There Is No Single Blue Cross Answer
People often talk about Blue Cross Blue Shield as though it were one national insurer with one rulebook. It is not. The Blue Cross Blue Shield Association is a national federation of 34 independent, community-based and locally operated companies, each licensing the Blue brand for its own region. A Crohn's patient in Michigan, another in Florida, and another covered by Anthem in California may all hold a Blue card while sitting under three entirely separate medical policies and drug formularies. Even within one company, an employer group plan, an individual marketplace plan, and a Medicare Advantage plan can place the same drug differently. So a friend's experience getting Tremfya approved tells you little about what your specific plan will do.
The Role of Pharmacy Benefit Managers
Layered on top of the plan itself is the pharmacy benefit manager, or PBM, the company that actually administers the drug benefit and builds the formulary. Different Blue plans contract with different PBMs, and that choice shapes which drugs sit on the preferred list and what you must try first. Anthem Blue Cross and Blue Shield plans, for example, use CarelonRx as their pharmacy benefits manager, while other Blue companies work with Prime Therapeutics or other PBMs. Because Tremfya has a subcutaneous injection option alongside its intravenous induction, it can run through either the pharmacy benefit or the medical benefit depending on how it is given and how your plan classifies it. That billing path affects your prior authorization route and your share of the cost.
Tremfya as a Later-Line Crohn's Therapy
Tremfya works as an interleukin-23 antagonist, meaning it selectively binds the p19 subunit of interleukin-23 and blocks its interaction with the IL-23 receptor, a pathway that drives Crohn's inflammation. In the phase 3 GRAVITI study, 56.1% of patients on guselkumab reached clinical remission at week 12 versus 21.4% on placebo, and in the GALAXI-2 and GALAXI-3 trials guselkumab showed superiority to both placebo and ustekinumab at week 48. Despite this strong data, because the Crohn's indication is so new, many Blue plans still treat it as an agent you reach after other biologics, frequently requiring you to have failed a preferred anti-tumor necrosis factor drug first.
Step Therapy and Prior Authorization
Almost every Blue plan requires prior authorization before it will pay for Tremfya, and many add step therapy, which means documenting that cheaper or older treatments did not work or could not be tolerated before the newer drug is approved. Anthem's published medical drug criteria for interleukin-23 inhibitors, for instance, require an inadequate response, intolerance, or contraindication to prior therapy before approving guselkumab for Crohn's disease. This insurer practice can sit in tension with clinical guidance. The 2025 AGA living guideline favors early use of advanced therapies over a step-up approach for many patients, yet coverage policies still often gate newer agents behind step requirements.
How to Find Your Own Plan's Rules
To get a real answer, go to the source rather than guessing. Your member ID card and benefits portal name your specific Blue company and PBM, which is the starting point for everything else.
Pull your plan's published drug formulary and search for Tremfya or guselkumab to see its tier and any restriction notes.
Find the medical or pharmacy policy document for guselkumab on your insurer's provider or member site to read the exact prior authorization and step therapy criteria.
Call the member services number on your card and ask whether Tremfya for Crohn's runs through the pharmacy or medical benefit.
Bring these documents to your gastroenterology team so the prior authorization request matches your plan's wording from the start.
Building the Case for Approval
When a plan requires step therapy, the strongest prior authorization is one that anticipates the criteria and answers them up front. The most useful thing you can do is keep a clear record of every Crohn's therapy you have tried, including the drug name, the dates you took it, and why it was stopped, whether for loss of response, intolerance, or a side effect. That history is exactly what reviewers look for when deciding whether a later-line agent like Tremfya is justified. If the request is denied, you have the right to appeal, and a well-documented treatment timeline paired with your physician's letter of medical necessity gives the appeal its foundation. Because Tremfya is so newly approved for Crohn's, denials sometimes reflect outdated policy language, and pointing to the current FDA indication and your documented prior failures can be decisive.
The Bottom Line
There is no universal Blue Cross Blue Shield answer to whether Tremfya is covered for Crohn's disease, because there is no universal Blue Cross Blue Shield plan. Coverage, tier placement, the choice of PBM, and the step therapy you must clear all depend on the specific independent company that issued your policy and the benefit design your employer or marketplace selected. What stays constant is the path to certainty. Read your own formulary and medical policy, confirm the benefit route, document your full treatment history, and lean on your care team for the prior authorization and any appeal. A drug this new to the Crohn's setting rewards patients who come prepared with the paperwork their plan is looking for.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.